[The original nootropic and neuroprotective drug noopept potentiates the anticonvulsant activity of valproate in mice].
The influence of the original dipeptide drug noopept, known to possess nootrope, neuroprotector, and anxiolytic properties, on the anticonvulsant activity of the antiepileptic drug valproate has been studied on the model of corazole-induced convulsions in mice. Neither a single administration of noopept (0.5 mg/kg, i.p.) nor its repeated introduction in 10 or 35 days enhanced the convulsant effect of corazole, which is evidence that noopept alone does not possess anticonvulsant properties. Prolonged (five weeks) preliminary administration of noopept enhanced the anticonvulsant activity of valproate. This result justifies the joint chronic administration of noopept in combination with valproate in order to potentiate the anticonvulsant effect of the latter drug. In addition, the administration of noopept favorably influences the cognitive functions and suppresses the development of neurodegenerative processes.
Kravchenko
E V
EV
Ponteleeva
I V
IV
Trofimov
S S
SS
Lapa
V I
VI
Ostrovskaia
R U
RU
Voronina
T A
TA
D000818:Animals; D000927:Anticonvulsants / Q000819:agonists / Q000494:pharmacology*; D003292:Convulsants / Q000009:adverse effects / Q000494:pharmacology; D004151:Dipeptides / Q000819:agonists / Q000494:pharmacology*; D004357:Drug Synergism; D008297:Male; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018697:Nootropic Agents / Q000819:agonists / Q000494:pharmacology*; D010433:Pentylenetetrazole / Q000009:adverse effects / Q000494:pharmacology; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*; D013997:Time Factors; D014635:Valproic Acid / Q000819:agonists / Q000494:pharmacology*
D000927:Anticonvulsants; D003292:Convulsants; D004151:Dipeptides; D018696:Neuroprotective Agents; D018697:Nootropic Agents; C103871:ethyl phenylacetyl-Pro-Gly; D014635:Valproic Acid; D010433:Pentylenetetrazole